Skip to main content
placeholder image

A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.

Journal Article


Abstract


Publication Date


  • 2010

Citation


  • Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599

Web Of Science Accession Number


Start Page


  • 2599

End Page


  • 2599

Volume


  • 28

Issue


  • 15_suppl

Abstract


Publication Date


  • 2010

Citation


  • Molife, L. R., Forster, M. D., Krebs, M., Pwint, T., Middleton, M. R., Kaye, S. B., . . . Ranson, M. (2010). A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors.. Journal of Clinical Oncology, 28(15_suppl), 2599. doi:10.1200/jco.2010.28.15_suppl.2599

Web Of Science Accession Number


Start Page


  • 2599

End Page


  • 2599

Volume


  • 28

Issue


  • 15_suppl